Ceftaroline now licensed for use in children

The parenteral cephalosporin, ceftaroline (Zinforo), has been approved for use in children aged two months and over. As in adults, the drug is indicated for the treatment of complicated skin and soft tissue infections (SSTI) and community-acquired pneumonia (CAP).

Further information
View Zinforo drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca

Zinforo is administered by intravenous infusion over 60 minutes every eight to 12 hours and should be continued for five to seven days in CAP and for five to 14 days in SSTI.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases